Balancing toxicity and effectiveness in older adults with B-cell acute lymphocytic leukaemia

Affiliations

¹ Department of Internal Medicine, Section of Hematology/Oncology, University of Cincinnati Cancer Center, Cincinnati, OH 45267, USA. Electronic address: curraney@ucmail.uc.edu.

Comment

Emily Curran. Lancet Haematol. 2023 Jun.

. 2023 Jun;10(6):e393-e394.

doi: 10.1016/S2352-3026(23)00113-8. Epub 2023 May 12.

¹ Department of Internal Medicine, Section of Hematology/Oncology, University of Cincinnati Cancer Center, Cincinnati, OH 45267, USA. Electronic address: curraney@ucmail.uc.edu.

No abstract available

Conflict of interest statement

I am on advisory boards for Kite, Amgen, Incyte, Pfizer, Servier, and Jazz Pharmaceuticals.

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Jabbour E, et al. Lancet Haematol. 2023 Jun;10(6):e433-e444. doi: 10.1016/S2352-3026(23)00073-X. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187201 Free PMC article. Clinical Trial.